Cardiac and Pulmonary Transplantation Pediatric lung transplantation

The application of lung transplantation to the pediatric population was a natural extension of the success realized in our adult transplantation program, which began in 1982. Twenty pediatric patients (age range 3 to 18 years) have had heart-lung (n = 11), double lung (n = 8), and single lung (n = 1) transplantation procedures. The causes of end-stage lung disease were primary pulmonary hypertension (n = 7), congenital heart disease (n = 5), cystic fibrosis (n = 4), pulmonary arteriovenous malformation (n = 2~ graft-versus-host disease (n = 1), and desquamative interstitial pneumonitis (n = 1). Four (20 %) patients had thoracic surgical procedures before the transplantation operation. The survival was 80 % at a mean foUow-up of 2 years. Immunosuppressive drugs included cyclosporine (n = 9) or FK 506 (n = 11) based therapy with azathioprine and steroids. Children were foUowed up by means of spirometry, transbronchial biopsy, and primed lymphocyte testing of bronchoalveolar lavage fluid. The mean number of treated episodes of rejection was 1.4 at 30 days, 0.5 at 30 to 90 days, and 1.4 at more than 90 days, and the first treated rejection episode occurred on average 28 days after the operation. Obliterative bronchiolitis developed in four (25 %) of 16 patients surviving more than 100 days. Results of pulmonary function tests have remained good in almost aU recipients. The greatest infectious risk was that of cytomegalovirus: one death and one case of pneumonia. Posttransplantation Iymphoproliferative disease was diagnosed in two (12.5 %) patients; both recovered. The most common complications were hypertension (25 %) and postoperative bleeding (15 %). Early results indicate that lung transplantation is a most promising therapy for children with severe vascular and parenchymal lung disease. (J THORAC CARDIOVASC SURG 1993;105:337-46)